Renin-Angiotensin-Aldosterone System Modulators in Adults with Hypertension: A Network Meta-Analysis of Randomized Controlled Trials
Drugs · 2024-11 · 84 (11) · 1445-1462
DOI: 10.1007/s40265-024-02092-7 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Drugs, online erschienen am 23.09.2024. Verfasst von Xiaoyan Yi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi St, Chongqing, 400016, China. Hauptthemen laut MEDLINE: Renin-Angiotensin System, Randomized Controlled Trials as Topic, Hypertension, Angiotensin-Converting Enzyme Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 90 Literaturangaben. Gefördert von: National Natural Science Foundation of China, national key research & development plan of China, Joint Medical Research Project of Chongqing Science and Technology Commission & Chongqing Health and Family Planning Commission.
Abstract (Originalsprache)
BACKGROUND: Although a range of renin-angiotensin-aldosterone system (RAAS) modulators are available for blood pressure lowering, the optimal choice within this class remains unclear. We aimed to compare the efficacy and safety of RAAS modulators in the adult hypertensive population. METHODS: A systematic literature search was performed in PubMed, CENTRAL, and Embase. The primary efficacy outcome was all-cause mortality and the secondary efficacy outcome was cardiovascular mortality. Tolerability outcome was discontinuation due to adverse events. Safety outcomes included the occurrence of cough, dizziness, edema, hyperkalemia, and hypotension. Network meta-analyses were performed utilizing a random-effects model within a frequentist framework. RESULTS: We finally identified 51 articles from 49 randomized controlled trials. When compared to placebo, mineralocorticoid receptor antagonists (MRAs) significantly reduced the risk of all-cause mortality (odds ratio (OR) 0.83; 95% confidence interval (CI) 0.74-0.92) and cardiovascular mortality (OR 0.79; 95% CI 0.68-0.93), while none of other RAAS modulators significantly lowered the risk of all-cause or cardiovascular mortality. Individual comparisons indicated that MRAs were associated with a significantly lower risk of all-cause mortality than the other RAAS modulators (reduction: 16% compared with angiotensin-converting enzyme inhibitors (ACEIs), 14% compared with angiotensin receptor blockers (ARBs), and 22% compared with direct renin inhibitors (DRIs)). No difference in discontinuation due to adverse events was found in a comparison of RAAS modulators with placebo. With regard to safety outcomes, ACEIs have a higher risk of cough (OR 4.68; 95% CI 1.61-13.60), ARBs have a higher risk of dizziness (OR 1.42; 95% CI 1.06-1.91), hypotension (OR 2.10; 95% CI 1.02-4.34), and hyperkalemia (OR 1.99; 95% CI 1.17-3.41), and MRAs had a higher risk of hyperkalemia (OR 2.68; 95% CI 1.99-3.62) when compared to placebo. CONCLUSIONS: MRAs were the only RAAS modulators with a survival benefit in adults with hypertension, although they carried a higher risk of hyperkalemia. Our data challenge current hypertension guidelines which recommend MRAs as fourth-line therapy, and suggest that MRAs should be prescribed earlier and more widely. REGISTRATION: PROSPERO identifier number CRD42023405714.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi St, Chongqing, 400016, China.
- The First Branch, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, VIC, Australia.
- Department of Medicine, Monash University, Clayton, VIC, Australia.
- Graduate Administration Office, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi St, Chongqing, 400016, China. liqifu@yeah.net.
Förderung
- National Natural Science Foundation of China
- national key research & development plan of China
- Joint Medical Research Project of Chongqing Science and Technology Commission & Chongqing Health and Family Planning Commission
- Chongqing Outstanding Youth Funds
- Program for Youth Innovation in Future Medicine, Chongqing Medical University
- Program for Major Scientific and Technological Talents, Chongqing Medical University
Zitieren
APA
Yi, X., Yang, S., Yang, J., Chen, X., Zhang, A., Zeng, Q., Luo, W., Li, Q., & Hu, J. (2024). Renin-Angiotensin-Aldosterone System Modulators in Adults with Hypertension: A Network Meta-Analysis of Randomized Controlled Trials. Drugs, 84(11), 1445-1462. https://doi.org/10.1007/s40265-024-02092-7
Vancouver
Yi X, Yang S, Yang J, Chen X, Zhang A, Zeng Q, et al. Renin-Angiotensin-Aldosterone System Modulators in Adults with Hypertension: A Network Meta-Analysis of Randomized Controlled Trials. Drugs. 2024;84(11):1445-1462. doi:10.1007/s40265-024-02092-7
BibTeX
@article{Yi2024,
author = {Yi, Xiaoyan and Yang, Shumin and Yang, Jun and Chen, Xiangjun and Zhang, Aipin and Zeng, Qinglian and Luo, Wenjin and Li, Qifu and Hu, Jinbo},
title = {Renin-Angiotensin-Aldosterone System Modulators in Adults with Hypertension: A Network Meta-Analysis of Randomized Controlled Trials},
journal = {Drugs},
year = {2024},
volume = {84},
number = {11},
pages = {1445--1462},
doi = {10.1007/s40265-024-02092-7}
}
EUVIMED